Amyloidosis is a rare disease characterized by the buildup of abnormal protein deposits called amyloid in various tissues and organs. When these deposits affect the eyes, they can lead to significant vision problems. Understanding the connection between amyloidosis and eye health is crucial for early detection and management.

What is Amyloidosis?

Amyloidosis occurs when amyloid proteins accumulate in tissues, disrupting normal function. It can affect multiple organs, including the heart, kidneys, nervous system, and eyes. There are different types of amyloidosis, with AL amyloidosis being the most common. The disease can be systemic, impacting the entire body, or localized, affecting specific areas.

How Amyloidosis Affects the Eyes

When amyloid deposits form in the eye, they can impact various structures, leading to symptoms such as vision changes, discomfort, or even loss of sight. Common ocular manifestations include:

  • Conjunctival deposits: Amyloid can deposit in the conjunctiva, causing a yellowish or pinkish appearance.
  • Lens involvement: Amyloid may lead to cataracts, resulting in blurred vision.
  • Retinal changes: Deposits in the retina can impair visual acuity.
  • Glaucoma: Amyloid buildup can obstruct fluid drainage, increasing eye pressure.

Signs and Symptoms to Watch For

Early detection of eye involvement is important. Be alert for symptoms such as:

  • Sudden or gradual vision loss
  • Blurred or distorted vision
  • Seeing floaters or spots
  • Eye redness or swelling
  • Light sensitivity or glare

When to Seek Medical Attention

If you or your patients experience any of these symptoms, especially in the context of known amyloidosis, consult an ophthalmologist promptly. Early diagnosis can help prevent irreversible damage and guide appropriate treatment strategies.

Conclusion

Amyloidosis can significantly impact vision through various ocular manifestations. Awareness of the symptoms and early intervention are key to preserving eye health. Regular eye examinations are recommended for individuals diagnosed with amyloidosis or experiencing related symptoms.